Clinical Trial: A Phase 1 Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746817) titled 'A Phase 1 Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis' on July 09.

Brief Summary: This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis. Parts A and B are randomized, double-blind, placebo-controlled single and multiple ascending dose cohorts in healthy adults, that will assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of BYN-001. Part C will assess BYN-001 in adults with moderate to severe atopic dermatitis.

Study Start Date: Aug. 01

Study Type: IN...